Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 ...

Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

The International Federation of Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief ...

Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on ...

The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...

BRL Medicine raised $27 million in a Series B+ round, led by CSPC Fund, to advance its gene and cell therapies for genetic ...

Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Roche’s Phase III SKYSCRAPER-01 trial missed its primary endpoint, with tiragolumab combined with Tecentriq failing to ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

Lexicon Pharmaceuticals is shifting focus to its late-stage pipeline following the FDA's rejection of Zynquista for type 1 ...

US central nervous system (CNS) disorders specialist Axsome Therapeutics (Nasdaq: AXSM) today released encouraging late-stage ...